Gerald Greer
Internal Medicine · Kokomo, INNPI 1700882701
Payments from drug & device makers
Across 415 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$869
- Novo Nordisk$752
- Otsuka America Pharmaceutical, Inc.$735
- Axsome Therapeutics, Inc.$544
- AstraZeneca$531
- plus $4K from 37 others
What the payments were for
- Food & beverage$8,92999%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,036 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $29,063 |
| TrulicityDulaglutide | 25 | $24,707 |
| MounjaroTirzepatide | 12 | $13,108 |
| JardianceEmpagliflozin | 12 | $7,106 |
| Levothyroxine Sodium | 30 | $653 |
| Diclofenac Potassium | 22 | $634 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $567 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $547 |
| Amlodipine Besylate | 94 | $332 |
| Trazodone Hcl | 56 | $252 |
| Lisinopril | 72 | $245 |
| Atorvastatin Calcium | 73 | $240 |
| Chlorhexidine Gluconate | 11 | $228 |
| Gabapentin | 31 | $225 |
| Fenofibrate | 16 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $869 | $37,81537 claims |
| Novo NordiskOzempic | $752 | $29,06328 claims |
| Boehringer IngelheimJardiance | $122 | $7,10612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Kokomo
- Lance WashingtonKokomo$53K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.